207 related articles for article (PubMed ID: 34231105)
21. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of Dmax and %ΔSUVmax of
Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
[TBL] [Abstract][Full Text] [Related]
23. [The role of PET/CT investigation in the management of patients with diffuse large B-cell lymphoma].
Paksi M; Demeter J; Szabó P
Magy Onkol; 2016 Jun; 60(2):108-17. PubMed ID: 27275637
[TBL] [Abstract][Full Text] [Related]
24. [Diagnostic and Prognostic Value of
Chen X; Qiao WL; Song JH; Liu CC; Han L; Wu S; Zhao JH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1044-1049. PubMed ID: 37551475
[TBL] [Abstract][Full Text] [Related]
25. Integration of PET in DLBCL.
Lewis KL; Trotman J
Semin Hematol; 2023 Nov; 60(5):291-304. PubMed ID: 38326144
[TBL] [Abstract][Full Text] [Related]
26. PET/CT: Clinical role in lymphomas.
Papathanasiou N
Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
[No Abstract] [Full Text] [Related]
27. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
28. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.
Shah NN; Nagle SJ; Torigian DA; Farwell MD; Hwang WT; Frey N; Nasta SD; Landsburg D; Mato A; June CH; Schuster SJ; Porter DL; Svoboda J
Cytotherapy; 2018 Dec; 20(12):1415-1418. PubMed ID: 30385043
[TBL] [Abstract][Full Text] [Related]
29. [
Xu HQ; Song LJ; Ding CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
[TBL] [Abstract][Full Text] [Related]
30. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
Mylam KJ; Nielsen AL; Pedersen LM; Hutchings M
PET Clin; 2014 Oct; 9(4):443-55, vi. PubMed ID: 26050946
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
Kandeel AA; Hussein M; Zidan L; Younis J; Edesa W; Alsayed Y
Nucl Med Commun; 2020 Mar; 41(3):269-279. PubMed ID: 31895758
[TBL] [Abstract][Full Text] [Related]
32. CT and
Altinmakas E; Üçışık-Keser FE; Medeiros LJ; Ng CS
Acad Radiol; 2019 Jun; 26(6):e108-e114. PubMed ID: 30076085
[TBL] [Abstract][Full Text] [Related]
33. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
Karls S; Shah H; Jacene H
Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
[TBL] [Abstract][Full Text] [Related]
34. Distinct FDG PET/CT avidity among newly diagnosed intravascular large B-cell lymphoma patients: a descriptive observational study.
Zhao D; Zhang Y; Zhu W; Huo L; Zhou D; Wang W; Wei C; Zhang W
Ann Hematol; 2024 Feb; 103(2):545-552. PubMed ID: 37932469
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
[No Abstract] [Full Text] [Related]
36. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
37. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
38. Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma.
Lavi N; Shapira G; Zilberlicht A; Benyamini N; Farbstein D; Dann EJ; Bar-Shalom R; Avivi I
Isr Med Assoc J; 2016 Jul; 18(7):411-417. PubMed ID: 28471564
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
40. Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma.
Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Cho H; Chung H; Min YH; Yang WI; Cho A; Kim JS
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S245-S252. PubMed ID: 32550718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]